U.S., June 4 -- ClinicalTrials.gov registry received information related to the study (NCT07622784) titled 'Pirtobrutinib Maintenance After CAR-T Therapy in Relapsed or Refractory B-Cell Lymphoma' on May 28.
Brief Summary: This is a single-arm, open-label, multicenter clinical study to evaluate the efficacy and safety of pirtobrutinib as maintenance therapy in patients with relapsed or refractory B-cell lymphoma after commercial anti-CD19 CAR-T cell therapy.
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Relapsed or Refractory B-cell Lymphoma
Intervention:
DRUG: Pirtobrutinib
Pirtobrutinib will be administered orally at a dose of 200 mg once daily for 6 months, beginning on Day 30 after commercial anti-CD19 CAR-T...